多菌种益生菌对自闭症症状的影响:PROBAUT随机对照试验方案
主要结局为用自闭症症状评定量表(ASRS)评估核心自闭症症状,次要结局包括生活质量、睡眠障碍、父母压力、胃肠道症状及尿对甲酚水平,在基线和12周后各评估一次。
要点
- 多菌种益生菌混合物每剂含5×10^9 CFU,含8种菌株,干预12周。
- 主要结局为ASRS评估的核心自闭症症状,基线和12周各评估一次。
- 次要结局包括生活质量、睡眠、父母压力、胃肠道症状和尿对甲酚。
核心结论
- 该方案旨在评估12周多菌种益生菌补充对ASD儿童核心自闭症症状严重程度的影响。
主要发现
- 原文为试验方案,尚未报告结果。
关键数值与推荐
- 益生菌混合物每剂含5×10^9 CFU,包含Bacillus subtilis W20、Bifidobacterium infantis W17、Bifidobacterium lactis W51、Lactobacillus acidophilus W37、Levilactobacillus brevis W63、Lacticaseibacillus rhamnosus W140、Lactococcus lactis W19和Propionibacterium freudenreichii W200。
- 主要结局为使用自闭症症状评定量表(ASRS)评估核心自闭症症状。
- 次要结局包括生活质量、睡眠障碍评估、父母压力水平、胃肠道症状和尿对甲酚水平。
- 所有结局在基线和12周干预后各评估一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Autism spectrum disorder (ASD) affects millions of children worldwide, negatively impacting the daily functioning and quality of life of patients and their families. New therapeutic approaches for ASD are being investigated. Probiotics have shown promise in modulating gut microbiota and ameliorating ASD symptoms. We aim to evaluate the impact of a 12-week multispecies probiotic supplementation on the severity of core autism symptoms in children with ASD. METHODS AND ANALYSIS: This study is a randomized, double-blind, placebo-controlled clinical trial. One hundred and 10 children aged 7 to 15 years diagnosed with ASD will be randomly assigned in a 1:1 ratio to receive either a probiotic mixture or a placebo for 12 weeks. The probiotic mixture contains 5 × 109 colony-forming units per dose of Bacillus subtilis W20, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Levilactobacillus brevis W63, Lacticaseibacillus rhamnosus W140, Lactococcus lactis W19, and Propionibacterium freudenreichii W200. The primary outcome will be the assessment of core autism symptoms using the Autism Symptom Rating Scales (ASRS). The secondary outcomes will include the quality of life, evaluations of sleep impairments, parental stress levels, gastrointestinal symptoms, and urinary p-cresol levels. These outcomes will be assessed twice: at baseline and after 12 weeks of intervention. ETHICS AND DISSEMINATION: The study has received approval from the Ethics Committee of the Medical University of Warsaw. Results will be submitted to a peer-reviewed journal and presented at national and international scientific meetings. TRIAL REGISTRATION: NCT06448767. Registered on 3 June 2024 Protocol version Version 2, 27 of October 2025.
引用
- Kotowska-Bąbol M, Konowałek Ł, Szajewska H, et al. Effect of multispecies probiotics on autism symptoms: protocol for a randomized controlled trial (PROBAUT). Trials. 2025. PMID: 41422017. doi:10.1186/s13063-025-09373-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。